Introduction

HIGHLIGHTS

• who: BJB and colleagues from the Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer (LC), is primarily classified into two subtypes, namely, lung adenocarcinoma and squamous cell carcinoma [1]NSCLC treatment is improved with the clinical implementation of targeted therapies, including the adoption of small-molecule tyrosine kinase inhibitors and antibodies targeting, cell receptor programmed cell death, and its ligand [2, ]. Despite the advent of such therapeutic modalities, the prognoses of NSCLC patients remain dismal, which can be attributed to late diagnosis and high metastatic potential of Department of Oncology, Beijing Luhe . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.